Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK2340272A (H1N1) in Adults
NCT00975884Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Primary completion
- Apr 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Q-Pan H1N1 in influenza (2 arms), sponsored by GSK. Primary endpoints: Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies at Day 21, Number of Subjects Who Were Seroprotected (SPR) for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain at Day 21 and 1 more. Started Sep 2009; status: completed.
02
Drugs
Q-Pan H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00975884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00975884.